ERAS

ANALYST NOTE: ERASCA, INC. (ERAS) DATE: 2026-06-13 CURRENT PRICE: $13.67

1. Structural Readiness

State: Context-Only (No Technical Structure Defined) Conservative Entry: — Breakout Level: — Extension: — ATR Current: 8.7% (Extreme)

Analysis:

2. Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Oncology (Tier Direct) Confidence: High

Thesis Narrative: Erasca is a direct beneficiary of the secular shift toward precision oncology targeting the RAS/MAPK pathway, specifically the KRAS and NRAS mutations. The company is singularly focused on discovering and commercializing therapies for these hard-to-drug targets.

• Direct Exposure: The company's pipeline is entirely aligned with the "RAS/MAPK" thesis. As noted in management's 2026 filings, molecular alterations in RAS account for over 5 million new cancer diagnoses globally annually.
• Therapeutic Focus: The company targets KRAS-mutant solid tumors (approx. 230,000 US patients annually) and NRAS-mutant melanoma (approx. 25% of melanoma cases, associated with worse prognosis).
• Conviction Weighting: The thesis is reinforced by the company's strategic pivot to a "modality-agnostic" approach, targeting upstream nodes (SHP2), direct RAS inhibition, and downstream escape routes (ERK). This multi-pronged strategy within a single high-conviction secular theme (Oncology) provides a robust structural foundation for the business, assuming clinical execution.

3. The Business

Company Profile: Erasca, Inc. is a clinical-stage precision oncology company focused on the RAS/MAPK pathway. The business model relies on advancing a proprietary pipeline of small-molecule inhibitors through clinical trials to achieve regulatory approval and commercialization, supplemented by licensing and milestone revenue.

Key Business Activities & Evidence (as of 2026-06-13):

• Pipeline Progress:
• SEACRAFT-2 (ERAS-4001): Management expects a randomized readout from Stage 1 of this pivotal Phase 3 study in 2025 (per 2024 transcript). As of March 2026, the company is advancing dose optimization. The study utilizes a two-stage design aligned with US and European authorities: Stage 1 for dose optimization and Stage 2 for regulatory approval.
• AURORAS-1 & JYP0015M101: Management anticipates Phase 1 monotherapy data readouts in the first half of 2026. Expansion cohorts and combination dose escalation are planned for the second half of 2026, with data readouts expected in 2027.
• BOREALIS-1: The IND was cleared by the FDA in May 2025. Management anticipates Phase 1 monotherapy data readouts in the second half of 2026.
• ERAS-4 (Pan-KRAS): A preclinical program focused on developing compounds for KRAS mutant solid tumors was announced in 2024 and remains in the preclinical phase as of the latest filings.
• Strategic Partnerships:
• Joyo License Agreement: In March 2026, the Company exercised an option to expand its territory to include mainland China, Hong Kong, and Macau. Based on feedback that Joyo had dosed the first patient in a Phase 2 trial, the Company made a corresponding payment of $150.0 million (less withholding) to Joyo.
• Milestone Obligations: The Company is obligated to make development and regulatory milestone payments of up to $57.5 million (post-expansion) and commercial milestone payments of up to $125.0 million upon achievement of corresponding milestones.
• Financial Position:
• Cash Runway: As of the March 31, 2026 financial statements, the Company believes its cash, cash equivalents, and marketable securities are sufficient to fund operations for at least one year from the issuance date.
• Historical Context: In March 2024, the Company reported $322 million in cash plus a $45 million oversubscribed equity financing, revising its runway guidance to the second half of 2026.

4. Archetype and Valuation Context

Archetype: Clinical-Stage Growth Leader / Deep Value Recovery (Conditional) Valuation Context:

• Financial Spine: Forward consensus EPS for FY1 is projected at -$0.96 and FY2 at -$0.56. The financial spine coverage is "complete," indicating a clear path to negative earnings for the near term, typical of clinical-stage biotechs.
• Conviction Stack:
• Thesis Strength: High. The RAS/MAPK pathway is a validated, high-value target with significant unmet medical need.
• Evidence Quality: Strong. Multiple Phase 3 and Phase 1 trials are active or anticipated in 2026, with specific data readout dates provided by management.
• Structural Quality: Moderate. The company has secured significant capital ($150M payment to Joyo implies strong partnership confidence, though cash outflow is noted) and regulatory alignment. However, the "Extreme" ATR (8.7%) suggests high volatility and potential liquidity risk or binary event sensitivity.
• Rerating Potential: High, contingent on the successful readout of SEACRAFT-2 Stage 1 and the AURORAS-1/BOREALIS-1 data in H1/H2 2026.

ATR Analysis:

5. Invalidating Factors and Evidence Gaps

What Would Invalidate the Case:

• Clinical Failure: A negative or inconclusive readout from SEACRAFT-2 Stage 1 (dose optimization) or the Phase 1 monotherapy trials (AURORAS-1, BOREALIS-1) in 2026.
• Cash Depletion: If the $150M payment to Joyo, combined with ongoing burn, depletes cash reserves before the 2027 data readouts, forcing a dilutive financing event.
• Regulatory Setback: FDA or EMA rejection of the two-stage Phase 3 design for SEACRAFT-2.

What Would Strengthen the Case:

• Positive Data: Successful dose optimization and efficacy signals in SEACRAFT-2 Stage 1.
• Partnership Expansion: Additional licensing deals or milestone payments from Joyo or other partners.
• Cash Extension: Management revising cash runway guidance beyond the "one year" mark stated in the March 2026 filing.

Evidence Gaps:

• Specific Trial Outcomes: While management *anticipates* readouts in 2026, the actual data (efficacy, safety) for AURORAS-1, JYP0015M101, and BOREALIS-1 is not yet in the evidence base as of 2026-06-13 (readouts are anticipated for H1/H2 2026, implying they may be pending or just occurring).
• Post-Joyo Cash Position: The March 2026 filing states cash is sufficient for "at least one year," but the exact remaining cash balance after the $150M payment is not explicitly detailed in the provided snippets, creating a gap in precise liquidity assessment.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management anticipates Phase 1 data readouts for AURORAS-1 and BOREALIS-1 in 2026; SEACRAFT-2 Phase 3 design aligned with regulators; $150M payment to Joyo confirms partnership activity and territory expansion. Key risks: Extreme ATR (8.7%) indicates high volatility and binary event risk; Clinical trial failures could halt progress; Cash runway is limited to one year from March 2026, requiring successful financing or milestones. Sizing hint: Position size must be reduced significantly due to extreme volatility and lack of technical structure; treat as a binary event play rather than a trend play. Expected path: Price will likely remain volatile as the market awaits H1 2026 data readouts; a positive readout could trigger a structural breakout, while negative data could lead to a sharp decline. Expected horizon: 6 to 12 months (aligned with anticipated data readouts in H1 and H2 2026). Failure mode to watch: A close below the implied psychological support levels driven by a negative clinical data readout or a dilutive financing announcement.